L Fegn1, Zhi Wang. 1. *Department of Otolaryngology Head and Neck Surgery, Boston Medical Center, Boston University School of Medicine, Massachusetts, USA.
Abstract
OBJECTIVE: Skin cancer is the most common cancer, and often occurs in the head and neck region. This study aimed to investigate whether a combination of inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase, applied via a microemulsion delivery system, would be effective in topically inhibiting skin carcinogenesis. STUDY DESIGN: Randomised animal study. METHODS: Twenty-four nude mice were intradermally inoculated with carcinoma cells and then divided into three groups (eight animals each): group one received no treatment; group two received celecoxib alone; and group three received a combination of zileuton and celecoxib. Tumour incidence and growth were measured for 14 days. RESULTS: Both treatments significantly delayed the onset and development of tumours. However, the combined treatment had the best response (p < 0.01). CONCLUSION: The results clearly showed that topical treatment with either celecoxib alone or celecoxib plus zileuton significantly inhibited skin carcinogenesis, and that a combination of both agents had the best results.
OBJECTIVE:Skin cancer is the most common cancer, and often occurs in the head and neck region. This study aimed to investigate whether a combination of inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase, applied via a microemulsion delivery system, would be effective in topically inhibiting skin carcinogenesis. STUDY DESIGN: Randomised animal study. METHODS: Twenty-four nude mice were intradermally inoculated with carcinoma cells and then divided into three groups (eight animals each): group one received no treatment; group two received celecoxib alone; and group three received a combination of zileuton and celecoxib. Tumour incidence and growth were measured for 14 days. RESULTS: Both treatments significantly delayed the onset and development of tumours. However, the combined treatment had the best response (p < 0.01). CONCLUSION: The results clearly showed that topical treatment with either celecoxib alone or celecoxib plus zileuton significantly inhibited skin carcinogenesis, and that a combination of both agents had the best results.
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Traci A Wilgus; Alane T Koki; Ben S Zweifel; Donna F Kusewitt; Patricia A Rubal; Tatiana M Oberyszyn Journal: Mol Carcinog Date: 2003-10 Impact factor: 4.784
Authors: D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto Journal: Br J Pharmacol Date: 2012-09 Impact factor: 8.739
Authors: Arash Mohebati; Ginger L Milne; Xi Kathy Zhou; Anna J Duffield-Lillico; Jay O Boyle; Allison Knutson; Brian P Bosworth; Philip J Kingsley; Lawrence J Marnett; Powel H Brown; Esther G Akpa; Eva Szabo; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2013-05-16
Authors: Ulises D Orlando; Juan Garona; Giselle V Ripoll; Paula M Maloberti; Ángela R Solano; Alejandra Avagnina; Daniel E Gomez; Daniel F Alonso; Ernesto J Podestá Journal: PLoS One Date: 2012-07-13 Impact factor: 3.240